DRREDDY

Updates March 20 story with Novo Nordisk comment on Wegovy launch timing in paragraph 11

By Rishika Sadam

HYDERABAD, March 21 (Reuters) - Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.

U.S.-based Lilly LLY.N and Danish Novo Nordisk NOVOb.CO have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers' valuations.

Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial, its lowest doses, the company told Reuters exclusively. Its highest dose is 15 mg.

A patient in India may have to spend about $200 a month when taking a weekly dose of 5 mg, subject to doctor's prescription.

Mounjaro carries a list price of $1,086.37 for each monthly fill in the U.S., but the amount patients pay largely depends on their insurance plan. Lilly also offers 5 mg, 7.5 mg and 10 mg vials of Zepbound, with prices around $499 for a month's supply if customers pay directly in cash without any third-party entities.

Chemically known as tirzepatide, Mounjaro is currently sold in the UK and Europe under the same brand name for both diabetes and weight loss. It is sold as Zepbound for obesity in the U.S.

Lilly, however, said that the pricing in different geographies cannot be compared given significant variation in healthcare systems, economies and reimbursement policies in each country.

"(Mounjaro) launch is ahead of Novo Nordisk and the first mover advantage should help ... but pricing seems high (for the Indian market). At the highest dose, a patient will have to spend close to 700,000 rupees (around $8,100) per annum," Vishal Manchanda, analyst at Systematix Institutional Equities said.

Novo's weight-loss drug, Wegovy, can cost non-insured U.S. patients more than $1,000 a month.

Novo's India team has been pushing the global leadership to launch Wegovy as early as 2025 in the country as opposed to the company's target of a 2026 launch.

The drugmaker told Reuters that Wegovy has already been approved in India, but said it did not have a confirmed date for the medicine's launch there.

The company's shares were down 0.6% at 1145 GMT, underperforming the broader European market .STOXX. Shares of U.S.-based Lilly rose as much as 2.07% to $854.39 on Thursday.

Novo's stock has fallen over 12% so far this year, while Lilly's has jumped 8%.

Novo is not the only competition Lilly will have to confront in India. Local drugmakers such as Sun Pharma SUN.NS, Cipla CIPL.NS, Dr. Reddy's REDY.NS and Lupin LUPN.NS have been racing to make generic versions of these drugs to grab a share of the global market estimated to be worth $150 billion in the next decade.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

"The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India," said President and General Manager Winselow Tucker at Lilly India.

Obesity and diabetes rates in India, a country of more than 1.4 billion people, have been steadily climbing. The number of adults with diabetes is set to increase to over 124 million by 2045 from 74.2 million in 2021, according to International Diabetes Federation.

Meanwhile, a government survey conducted between 2019 and 2021 showed that 24% of women and nearly 23% of men between the ages of 15 and 49 were either overweight or obese, up from 20.6% of women and 19% of men in 2015-2016.

Wegovy and Novo's diabetes drug, Ozempic — which has the same main ingredient — and Mounjaro, belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.

($1 = 86.3425 Indian rupees)

(Reporting by Rishika Sadam in Hyderabad, Maggie Fick in London and Bhanvi Satija in Bengaluru; Additional reporting by Manvi Pant in Bengaluru; Editing by Janane Venkatraman, Alan Barona and Tomasz Janowski)

(([email protected]; [email protected]))

March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.

India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:

NOVO NORDISK

The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.

SUN PHARMA

Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.

The drugmaker said earlier this month it expects to launch the drug in the next four to five years.

BIOCON

Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.

ZYDUS LIFESCIENCES

India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.

CIPLA

Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.

Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.

DR. REDDY'S

India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.

LUPIN

India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.

NATCO, MANKIND PHARMA, AUROBINDO PHARMA

Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.

Reuters was not able to independently verify the reports.

(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

(([email protected];))

March 18 (Reuters) - Alvotech SA ALVO.O:

• ALVOTECH AND DR. REDDY'S ANNOUNCE FDA ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION FOR AVT03, A PROPOSED BIOSIMILAR TO PROLIA® AND XGEVA®

Source text: ID:nGNERlH6z

Further company coverage: ALVO.O

(Gdansk Newsroom)

(([email protected]; +48 58 7696600;))

March 13 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S LABORATORIES LTD - RECALLS LEVETIRACETAM INJECTION IN U.S.

• DR REDDY'S LABORATORIES LTD - RECALL DUE TO MISLABELING OF INFUSION BAG

• DR REDDY'S LABORATORIES LTD - NO ADVERSE EVENTS REPORTED RELATED TO RECALL

• DR REDDY'S LABORATORIES LTD - MISLABELED PRODUCT MAY CAUSE SERIOUS ADVERSE EVENTS

• DR REDDY'S LABORATORIES LTD - RECALL EXECUTED WITH KNOWLEDGE OF U.S. FDA

• DR REDDY'S - DUE TO MISLABELING OF INFUSION BAG

Source text: ID:nBSEYZGPz

Further company coverage: REDY.NS

(([email protected];;))

March 4 (Reuters) - Senores Pharmaceuticals Ltd SENO.NS:

• ACQUIRES 14 ANDAS FROM DR. REDDY'S LABORATORIES

• ACQUISITION INCLUDES 13 APPROVED ANDAS AND 1 PENDING APPROVAL

• ADDRESSABLE OPPORTUNITY OF ACQUIRED ANDAS IN USA APPROX. $421 MILLION

Source text: ID:nBSEcxCc7

Further company coverage: SENO.NS

(([email protected];;))

By Rishika Sadam and Kashish Tandon

MUMBAI/BENGALURU, Feb 28 (Reuters) - Tariffs should not influence decisions at Indian drug companies, Cipla's CIPL.NS top executive said on Friday, as the industry braces for U.S. President Donald Trump's plans to tax pharmaceutical imports.

India, often dubbed the "pharmacy of the world", is among the top exporters to the U.S., especially for cheaper versions of popular drugs.

"I'm not sure tariffs should dictate what we should be doing as players, because there is a risk that four years later, those tariffs may go away," Cipla Global CEO Umang Vohra said at the Global Pharmaceutical Quality Summit in Mumbai.

"So by the time you build a plant, tariffs have gone away. Now you have a plant sitting there, right? So I just think we should take a more holistic view."

Trump has said he could impose duties of 25% or more on pharmaceutical imports and an announcement could be made by next month. He also asked companies to shift manufacturing to the U.S. to avoid tariffs.

Most drugmakers said they were awaiting clarity on what kind of tariffs would be imposed, if any.

"I don't know how much difference it (tariffs) will make to us... and will not justify relocating our manufacturing," said Sun Pharma SUN.NS MD Dilip Shanghvi.

"Ultimately, it (tariff impact) will be passed on to consumers," Shanghvi said.

India imposes an about 10% tax on pharma imports from the U.S. while paying almost nothing on exports of its pharmaceutical products into the U.S., according to industry experts.

India makes cheaper generic versions of complex innovative drugs in its massive factory clusters and exports them to over 200 countries, and the U.S. is its biggest market, government data shows.

According to research firm IQVIA, nearly half of all prescriptions for generic medicines in the United States in 2022 were supplied by Indian drugmakers. Overall, generic drugs saved the U.S. health system about $408 billion.

Earlier this week, Dr Reddy's MD GV Prasad told Reuters Indian drugmakers are likely to remain competitive in the generics market even if Trump levies a duty on pharmaceutical imports.

He had also said shifting manufacturing to the U.S. was not practical as they do not have enough capacity and costs would rise.

(Reporting by Rishika Sadam in Mumbai; Writing by Kashish Tandon; Editing by Devika Syamnath)

(([email protected];))

By Kashish Tandon, Bhanvi Satija and Rishika Sadam

HYDERABAD Feb 26 (Reuters) - The rising adoption of artificial intelligence in the pharmaceutical industry dominated discussions at a conference in India this week, while executives largely preferred to wait for more clarity on U.S. President Donald Trump's tariff threats.

Drugmakers such as Amgen AMGN.O and contract manufacturers including Parexel highlighted AI's role in reducing the time taken to conduct certain parts of the trials.

U.S.-based Parexel said it was piloting an AI model to generate drug safety reports 30-45 minutes faster than the manual process. The AI-generated reports are then verified by an expert.

AI can help halve the cost and time taken to develop a drug, from discovery through commercial production, compared to the traditional process, said Chaitanya Royyuru, partner at consulting firm EY. Royyuru estimated that the process currently takes more than 10 years and costs about $1 billion.

Discovering new molecules and drug repurposing, or using a drug for a condition outside of its approved indication, are other areas where AI is being utilized, executives said.

Beyond drug discovery processes, AI is also being used in medical image reading, where it is able to assist doctors in finding anomalies.

"Sometimes, when we look at an X-ray and we think it's normal, but AI says look, there's a small cancer you're missing," said Nageshwar Reddy, chairman, Asian Institute of Gastroenterology.

"And when we actually look at it very carefully and follow the patient, there's a cancer coming there," Reddy said.

Ken Washington, chief technological officer, Medtronic, said, "The bottom line is that AI has to be everybody's job."

WAIT AND WATCH ON TARIFFS

Trump's plans to levy tariffs on pharmaceutical imports had cast a shadow over the two-day conference as India is among the top exporters to the U.S., especially of cheaper versions of popular drugs.

However, drugmakers including Dr Reddy's REDY.NS said they were still waiting for clarity on the tariffs.

"Right now, it's wait and watch. There is no clarity on what the tariffs are, if any, or if there is a transition period," said Nandini Piramal, chairperson at Piramal Pharma, which provides contract manufacturing and development services.

(Reporting by Kashish Tandon, Bhanvi Satija and Rishika Sadam in Hyderabad; Editing by Sriraj Kalluvila)

(([email protected]; Outside U.S. +91 9873062788;))

Feb 25 (Reuters) - Indian drugmakers are likely to remain competitive in the generic drugs market in the face of U.S. President Donald Trump's plans to levy tariffs on pharmaceutical imports, Dr Reddy's Managing Director GV Prasad said on Tuesday.

The Indian pharmaceutical industry is still waiting for more clarity on any tariffs before taking any action given a lack of details, Prasad said on the sidelines of the BioAsia conference in the Southern Indian state of Telangana. The tariffs would likely raise costs for U.S. consumers or middlemen, he added.

"In reality, to shift all these products from worldwide into the United States is not practical. They don't have that much capacity, and their costs will rise. Even with tariffs, I think Indian and Chinese companies would be competitive."

(Reporting by Rishika Sadam in Hyderabad; Writing by Manas Mishra; Editing by Janane Venkatraman )

(([email protected]; www.twitter.com/Manaswrites15;))

Corrects paragraph 6 in February 20 story to say generic drugs overall, not just those supplied by Indian drugmakers, resulted in $408 billion in savings for the U.S. healthcare system

By Rishika Sadam

HYDERABAD Feb 20 (Reuters) - Indian drugmakers are hoping that bilateral discussions between the country and the United States will help them steer clear of President Donald Trump's plan to levy at least 25% tariffs on pharmaceutical imports, a trade association said.

India, which calls itself the 'pharmacy of the world', makes cheaper generic versions of complex innovative drugs in its massive factory clusters and exports them to over 200 countries, of which the U.S. is its biggest market, government data shows.

In fiscal 2024, the exports to the U.S. were worth $8.7 billion, or about 31% of total pharma exports, per data from government-backed trade body Pharmexcil. Trump's threat to raise tariffs sent shares of Indian drugmakers sliding on Wednesday.

"This (tariff) matter will be discussed through bilateral engagements between the two countries and further steps will be determined accordingly," Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance (IPA), said in a statement on Wednesday.

"We are confident that continued dialogue among stakeholders will help address the subject."

According to research firm IQVIA, nearly half of all prescriptions for generic medicines in the U.S. in 2022 were supplied by Indian drugmakers, underscoring the Indian industry's role in access to affordable, quality-assured medicines. Overall generic drugs saved the U.S. healthcare system about $408 billion that year.

"This (tariff) move is going to be inflationary to the U.S. as they don't have the requisite manufacturing infrastructure in-house to replace the scale of supply that India does," said Vishal Manchanda, an analyst at Systematix Institutional Equities.

The IPA represents some of India's biggest drugmakers, including Sun Pharmaceutical SUN.NS, Dr Reddy's REDY.NS, Cipla CIPL.NS and Zydus Lifesciences ZYDU.NS, as well as the local units of U.S. firms like Abbott ABT.N.

Earlier this week, Sun Pharma Managing Director Dilip Shanghvi told local media that the tariffs, if imposed, will be passed on to consumers.

(Reporting by Rishika Sadam; Editing by Savio D'Souza)

(([email protected];))

Feb 19 (Reuters) - Shares of Indian pharmaceutical companies .NIPHARM slid 2.2% on Wednesday after U.S. President Donald Trump said he intends to impose tariffs in the range of 25% on pharma imports.

Sun Pharma SUN.NS and Dr Reddy's REDY.NS fell 2% and 3.4%, respectively, while Aurobindo Pharma ARBN.NS tumbled 6%.

(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

** Shanghai Henlius Biotech 2696.HK soars 10.8% to HK$20.50; set for biggest one-day pct gain since June 25, 2024

** Stock hits highest since January 14; on course for fifth straight session of gains

** Biopharmaceuticals products maker grants India-based Dr. Reddy's Laboratories SA REDY.NS license to develop, manufacture and commercialise HLX15 in the U.S. and 42 European countries, including the UK and Switzerland, as it deepens overseas expansion

** Says Dr. Reddy's will pay $33 mln upfront and milestone payments of up to $98.6 mln in total and royalties of up to 8% of annual net sales

** HLX15 is used to treat multiple myeloma

** REDY up 0.1%; set for fourth straight session of gains

** Shanghai Henlius's stock soared 70.5% last year

(Reporting by Donny Kwok)

(([email protected]))

Feb 6 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK:

• LICENSE AGREEMENT WITH DR. REDDY'S FOR HLX15

• DR. REDDY'S SHALL PAY COMPANY US$33 MLN

• GRANTED DR. REDDY'S A LICENSE TO DEVELOP, MANUFACTURE AND COMMERCIALIZE HLX15

Source text: ID:nHKS92VVM6

Further company coverage: 2696.HK

(([email protected];))

Adds analyst comment in paragraph 5

By Kashish Tandon and Rishika Sadam

HYDERABAD/BENGALURU Jan 31 (Reuters) - Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, reported a bigger-than-expected quarterly profit on Friday, aided by strong sales in the domestic market.

The Mumbai-based firm's consolidated net profit rose 15% to 29.03 billion rupees ($335.3 million) in the third quarter, beating analysts' average estimate of 28.81 billion rupees, according to data compiled by LSEG.

Sales in India, Sun Pharma's largest revenue-generating region, rose 14% to 43 billion rupees, or about 31% of total sales. That was bigger than the 11% increase in the previous quarter.

Its high-margin global specialty pharmaceutical segment, which includes medicines for conditions such as alopecia and psoriasis, reported a 17.5% jump in sales to $370 million, or 21% of total sales.

"Increasing contribution from global specialty drugs is a key positive for Sun Pharma and will continue to boost margins in near term, said Shrikant Akolkar, an analyst at Nuvama Institutional Equities.

Overall, the company's revenue rose 10.5% to 136.75 billion rupees, surpassing analysts' estimates of 134.22 billion rupees.

That was despite U.S. sales increasing just 0.7%.

Most of India's generic drugmakers derive a significant share of revenue from the United States, where lower drug prices due to stiff competition have been weighing on profit margins.

Among its rivals, Dr Reddy's REDY.NS missed profit estimates for the quarter, while Cipla CIPL.NS beat expectations. However, both the generic drugmakers saw muted growth in their key North American market.

($1 = 86.5860 Indian rupees)

(Reporting by Rishika Sadam and Kashish Tandon; Editing by Savio D'Souza)

(([email protected];))

Jan 24 (Reuters) - Shares of Dr Reddy's Laboratories REDY.NS dropped 6% in early trade on Friday, a day after the company reported a third-quarter profit that fell short of market estimates due to lower sales and pricing pressures in the key North American market.

The generic drugmaker's shares were on track for their worst day in nearly nine months and were the top loser on the benchmark Nifty 50 .NSEI index, which was 0.3% higher.

Indian generic drugmakers are struggling with slower sales in the United States, delayed approvals for new drug applications and lower pricing amid stiff competition.

At least four brokerages slashed price targets on Dr Reddy's stock, while three cut their ratings, LSEG data showed.

(Reporting by Manvi Pant in Bengaluru; Editing by Savio D'Souza)

(([email protected]; +918447554364;))

Jan 23 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• Q3 CONSOL NET PAT 14.14 BILLION RUPEES; IBES EST. 14.89 BILLION RUPEES

• Q3 CONSOL TOTAL REV FROM OPS 83.81 BLN RUPEES; IBES EST. 81.23 BLN RUPEES

Source text: [ID:]

Further company coverage: REDY.NS

(([email protected];;))

• Dr Reddy's Laboratories Ltd RDY.N, RDY is expected to show a rise in quarterly revenue when it reports results on January 23 for the period ending December 31 2024

• The Hyderabad Telangana-based company is expected to report a 12.4% increase in revenue to ₹81.331 billion from ₹72.37 billion a year ago, according to the mean estimate from 20 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Dr Reddy's Laboratories Ltd is for earnings of ₹16.61 per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $17.00​, above​ its last closing price of $14.90. ​​​

Previous quarterly performance (using preferred earnings measure in Indian rupees). ​

This summary was machine generated January 21 at 11:17 GMT. All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected])

Jan 9 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S - GOT TAX ORDER FOR PENALTY 4 MILLION RUPEES

Source text: ID:nnAZN32FIPF

Further company coverage: REDY.NS

(([email protected];;))

Jan 8 (Reuters) - FDA:

• FDA: DR REDDY'S RAMELTEON TABLET 8 MG (NDC 43598-741-01),8 MG (NDC 43598-741-30),8 MG (NDC 50268-708-15),8 MG (NDC 72162-2169-3) DISCONTINUED- WEBSITE

Source text: [ID:]

Further company coverage: REDY.NS

Jan 7 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S LABORATORIES LTD - LABS INC AGREES TO SELL DRLL AND SHREVEPORT FACILITY

Source text: ID:nBSE5QdnWj

Further company coverage: REDY.NS

(([email protected];))

Dec 23 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S LABORATORIES LTD - INCORPORATES NEW WHOLLY-OWNED SUBSIDIARY IN FINLAND

Source text: ID:nBSE4JBtPB

Further company coverage: REDY.NS

(([email protected];;))

Dec 6 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S - UNIT REDDY’S LABORATORIES, UKRAINE RECEIVED ORDER FROM STATE TAX SERVICE, UKRAINE

Source text: ID:nBSE2tZ9KH

Further company coverage: REDY.NS

(([email protected];))

Dec 5 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S - KAZAKHSTAN UNIT GETS TAX ORDER FOR PENALTY AT 2.9 MILLION RUPEES

Further company coverage: REDY.NS

(([email protected];))

By Leroy Leo and Rishika Sadam

BENGALURU/HYDERABAD, Dec 3 (Reuters) - Novo Nordisk's NOVOb.CO team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular weight-loss drug Wegovy over fears of falling behind rival Eli Lilly LLY.N in the potentially huge market, two sources familiar with the plans told Reuters.

Officials at the Danish drugmaker have said Wegovy might be introduced in India in 2026 once regulatory approvals are in hand and there is sufficient supply. More recently, Novo's India team proposed moving the launch to next year, around the same time Lilly is expected to introduce its weight-loss drug Mounjaro.

In a closed-door meeting at Novo's Denmark headquarters about two months ago, the India team raised concerns that the company could lag behind Lilly in the domestic market if Wegovy was not launched early, said one of the sources, who spoke on condition of anonymity as they were not authorized to speak to the media.

Novo declined to comment on internal discussions and Reuters could not determine what response the India-based executives received.

Wegovy and Novo's diabetes drug Ozempic, which has the same main ingredient, and Mounjaro, belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.

The companies have been struggling to meet soaring demand in the U.S. and the few other countries where the drugs have been launched so far. Novo and Lilly are both scaling up production as they vie for a dominant share of a weight-loss market that some analysts forecast could reach $150 billion a year in the next decade.

Novo received regulatory approval in India for injectable semaglutide - the active ingredient in Wegovy and Ozempic - in late 2022, according to one of the sources.

"We are working to make Wegovy (semaglutide injection 2.4 milligrams) available as soon as possible. We do not yet have a confirmed date for launch," Novo India said in a statement to Reuters.

Lilly, in response to a Reuters request, said its 2025 Mounjaro launch is also subject to the supply situation.

Last month, Novo launched Wegovy in China, the world's second-largest pharmaceuticals market, pricing a month's supply of the starter dose at 1,400 yuan ($193.27), far lower than its U.S. list price of more than $1,300, although most people don't pay that much.

India's generic drugmakers, including Cipla CIPL.NS and Dr Reddy's REDY.NS, are making cheaper copies of Wegovy, with the timing of any launch subject to patent expiry. Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own experimental GLP weight-loss drug.

India, a country of more than 1.4 billion people, has seen an increase in the prevalence of obesity. A government survey conducted between 2019 and 2021 showed that 24% of women and nearly 23% of men between the ages of 15 and 49 were either overweight or obese, up from 20.6% of women and 19% of men in 2015-2016.

Dr. Rishma Pai, a consultant gynaecologist at three hospitals in Mumbai who participated in a Novo survey about attitudes towards obesity, said the company has been reaching out to many types of doctors for a few years to spread awareness about obesity medications and better understand how to promote their acceptance in India.

Acceptance no longer appears to be an issue.

"Every patient is asking about these weight-loss injections," Pai said.

(Reporting by Rishika Sadam in Hyderabad and Leroy Leo in Bengaluru; Editing by Michele Gershberg and Bill Berkrot)

(([email protected];[email protected];))

Nov 28 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S - LAUNCHES TORIPALIMAB IN INDIA

• DR REDDY'S - LAUNCHES TORIPALIMAB IN INDIA

Source text: ID:nBSE8Wcgf8

Further company coverage: REDY.NS

(([email protected];;))

Nov 19 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S - USFDA COMPLETED A GMP INSPECTION AT CO'S API MANUFACTURING FACILITY IN BOLLARAM,

• DR REDDY'S - ISSUED A FORM 483 WITH 7 OBSERVATIONS

• DR REDDY'S - INSPECTION WAS CONDUCTED FROM NOVEMBER 13 TO NOVEMBER 19

Source text: ID:nBSE4HTq9y

Further company coverage: REDY.NS

(([email protected];))

Nov 18 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• CLARIFICATION ON REPORT "DR REDDY'S, FDC RECALL PRODUCTS IN US FOR MANUFACTURING ISSUE"

• IN OCT INITIATED VOLUNTARY RETAIL-LEVEL RECALL OF 2 LOTS OF MORPHINE SULFATE EXTENDED-RELEASE TABLETS

• RECALL WAS VOLUNTARILY UNDERTAKEN BY CO OUT OF ABUNDANCE OF CAUTION

Source text: ID:nBSE8D5SK8

Further company coverage: REDY.NS

(([email protected];))

Nov 14 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS:

• DR REDDY'S LABORATORIES - MEXICO'S COFEPRIS IMPOSES PENALTY OF MXN 651,420

Further company coverage: REDY.NS

(([email protected];))

• Dr Reddy's Laboratories Ltd RDY.N reported quarterly adjusted earnings of ₹15.05​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of ₹17.78. The mean expectation of four analysts for the quarter was for earnings of ₹16.66 per share. Wall Street expected results to range from ₹15.26 to ₹17.75 per share.

• Revenue rose 16.5% to ₹80.38 billion from a year ago; analysts expected ₹76.47 billion.

• Dr Reddy's Laboratories Ltd's reported EPS for the quarter was ₹15.05​.

• The company reported quarterly net income of ₹12.56 billion.

• Dr Reddy's Laboratories Ltd shares had fallen by 8.1% this quarter and gained 5.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is 17.00

This summary was machine generated from LSEG data November 6 at 05:22 a.m. UTC. ​All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected])

Nov 5 (Reuters) - Indian generic drugmaker Dr Reddy's Laboratories REDY.NS reported a second-quarter profit that missed analysts' expectations on Tuesday, weighed down by pricing pressure in a competitive North American market, their biggest by revenue.

The company reported a 9.5% fall in its consolidated net profit after tax to 13.42 billion rupees ($159.6 million) for the quarter ended Sept. 30, missing analysts' estimate of 14.01 billion rupees, as per data compiled by LSEG.

($1 = 84.0710 Indian rupees)

(Reporting by Kashish Tandon and Rishika Sadam in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

• Dr Reddy's Laboratories Ltd RDY.N, RDY is expected to show a rise in quarterly revenue when it reports results on November 5 for the period ending September 30 2024

• The Hyderabad Telangana-based company is expected to report a 10.8% increase in revenue to ₹76.472 billion from ₹69.03 billion a year ago, according to the mean estimate from 17 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Dr Reddy's Laboratories Ltd is for earnings of ₹83.31 per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $87.00​, above​ its last closing price of $73.90. ​​​

Previous quarterly performance (using preferred earnings measure in Indian rupees). ​

This summary was machine generated November 1 at 14:12 GMT. All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected])